Early Inclisiran for High LDL-C in Atherosclerotic Cardiovascular Disease

Adding inclisiran to statin therapy led to significant and meaningful reduction of LDL-C without increasing statin discontinuation.

Most patients with atherosclerotic cardiovascular disease (ASCVD) do not achieve low-density lipoprotein cholesterol (LDL-C) goals. High-intensity statins reduce LDL-C, but real-world data demonstrate statin underutilization and under-intensification. Inclisiran is a small interfering RNA that inhibits hepatic PCSK9 production and is administered subcutaneously. It has been shown to reduce LDL-C levels by ≈50%, although clinical outcomes data are still pending.

VICTORIAN-INITIATE was an industry-sponsored, randomized, open-label trial of an “inclisiran-first” treatment strategy compared with usual care in 450 U.S. patients with known ASCVD and LDL-C ≥70 mg/dL on maximally tolerated statin therapy or with statin intolerance (25% of the cohort…

Reviewing Author

Shea E. Hogan, MD, MSCS, FACC, FSCAI, FSVM

Disclosures

Editorial BoardsVascular Medicine

Shea E. Hogan, MD, MSCS, FACC, FSCAI, FSVM

Disclosures

Editorial BoardsVascular Medicine

Early Inclisiran for High LDL-C in Atherosclerotic Cardiovascular Disease

Topics

Reviewing Author